People | February 15, 2025
AbbVie Appoints CEO Robert A. Michael as Chairman of the Board of Directors
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Subscribe To Our Newsletter & Stay Updated
